TAK
HealthcareTakeda Pharmaceutical Company Limited · Drug Manufacturers - Specialty & Generic · $51B
What is Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited is one of Japan's oldest and largest pharmaceutical companies, operating across major global markets. It focuses on specialty medicines in areas where patient need is high and treatment options are limited.
Takeda researches, develops, manufactures, and markets pharmaceutical products across gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company generates revenue through direct product sales and out-licensing agreements with partners worldwide. It also maintains a broad network of research collaborations and strategic alliances with biotech firms and academic institutions, aiming to expand its pipeline beyond its existing branded portfolio.
Takeda traces its origins to 1781 and is headquartered in Tokyo, Japan.
- Gastroenterology treatments including Entyvio for inflammatory bowel disease
- Rare disease therapies such as Elaprase, Replagal, and Vpriv
- Plasma-derived therapies including Gammagard Liquid and Hyqvia
- Oncology products including Adcetris and Alunbrig
- Neuroscience medicines including Vyvanse and Trintellix
Is TAK a Good Stock to Buy?
UQS Score rates TAK as Below Average overall.
Among the five pillars, Valuation stands out as Attractive — meaning the stock may be priced at a discount relative to its fundamentals, which can appeal to value-oriented investors willing to accept other trade-offs.
The Quality, Moat, Growth, and Risk pillars all register as Weak, reflecting meaningful challenges across profitability, competitive positioning, business momentum, and balance sheet stability.
See the exact pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TAK pay dividends?
Yes — Takeda Pharmaceutical Company Limited pays a dividend.
Takeda pays a regular dividend, which is relatively uncommon among large pharmaceutical companies still carrying significant debt from major acquisitions. The dividend reflects management's commitment to returning capital to shareholders, though investors should weigh this against the company's broader financial risk profile before relying on it as a primary income source.
When does TAK report earnings?
Takeda reports earnings on a quarterly cadence, consistent with standard practice for internationally listed pharmaceutical companies.
Revenue has been shaped by the performance of key branded products alongside ongoing pipeline investments. Cost pressures and debt servicing from past acquisitions continue to influence reported results. Trends in core therapeutic areas — particularly gastroenterology and rare diseases — remain central to how the market interprets each quarterly update.
For the most recent quarter's results, visit Takeda Pharmaceutical's official investor relations page.
TAK Price History
+23.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Takeda Pharmaceutical Company Limited?
Based on Takeda Pharmaceutical Company Limited's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
TAK Long-term Outlook
Given Weak ratings across Growth and Risk, the near-term fundamental outlook for TAK carries meaningful uncertainty. The company faces headwinds from a heavy debt load, pipeline execution risk, and competitive pressure in several therapeutic categories. The Attractive Valuation label suggests the market may already be pricing in these concerns, which could limit downside — but a sustained recovery would depend on pipeline progress and debt reduction.
Growth drivers
- Continued commercial performance of Entyvio in gastroenterology markets
- Expansion of rare disease and plasma-derived therapy franchises globally
- Pipeline partnerships and licensing agreements adding future revenue potential
Key risks
- Elevated debt levels from the Shire acquisition weighing on financial flexibility
- Patent expirations and biosimilar competition threatening key revenue streams
- Execution risk across a broad and complex global pipeline
TAK vs Peers
Takeda operates in a competitive global pharmaceutical landscape alongside companies with varying therapeutic focuses and business models.
Zoetis focuses exclusively on animal health, giving it a differentiated market position entirely separate from Takeda's human pharmaceutical focus.
Haleon concentrates on consumer healthcare brands rather than prescription medicines, representing a lower-risk but different growth profile than Takeda.
Teva is a global generics leader, competing on volume and cost efficiency rather than the branded specialty medicines that anchor Takeda's portfolio.
Frequently Asked Questions
What does Takeda Pharmaceutical do?
Takeda researches, develops, and sells prescription medicines across gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. It operates globally with a particularly strong presence in Japan, the United States, and Europe, and supplements its own pipeline through partnerships and licensing agreements with biotech companies and academic institutions.
Does TAK pay dividends?
Yes, Takeda pays a regular dividend. This is notable given the company's significant debt load from past acquisitions. Investors seeking income should review the current dividend level and payout sustainability in the context of Takeda's overall financial risk profile before making decisions.
When does TAK report earnings?
Takeda reports earnings on a quarterly basis, in line with standard practice for major internationally listed companies. For exact dates and the most recent financial results, check Takeda Pharmaceutical's investor relations page directly.
Is TAK a good stock to buy?
UQS Score rates TAK as Below Average, reflecting Weak readings across Quality, Moat, Growth, and Risk pillars. The Valuation pillar is Attractive, which may interest value-focused investors. Whether it fits a portfolio depends on individual risk tolerance and investment goals — the full pillar breakdown is available to Pro members.
Is TAK overvalued?
Based on UQS Score's Valuation pillar, TAK is rated Attractive — suggesting the stock may be trading at a discount relative to its fundamentals. This does not guarantee upside, particularly given the Weak readings in other pillars, but it does indicate the market appears to have priced in significant headwinds.
How does TAK compare to its competitors?
Compared to peers like Teva, Haleon, and Zoetis, Takeda occupies a distinct space as a large-cap specialty pharma focused on complex diseases. Each competitor operates in a different segment — generics, consumer health, or animal health — making direct comparisons nuanced. The UQS platform allows side-by-side pillar comparisons for a structured view.
What is TAK's market cap bracket?
Takeda is classified as a large-cap company, reflecting its scale as one of Asia's largest pharmaceutical firms with a global commercial footprint across multiple therapeutic areas and dozens of branded products.
Who founded Takeda Pharmaceutical?
Takeda Pharmaceutical was founded in 1781 by Chobei Takeda I in Osaka, Japan, originally as a medicine wholesaler. It has since grown over more than two centuries into one of the world's largest research-based pharmaceutical companies, now headquartered in Tokyo.
Is TAK a long-term quality investment?
As a long-term quality indicator, UQS Score currently rates TAK as Below Average. The Weak readings across Quality, Moat, and Growth pillars suggest the company faces structural challenges that could limit compounding potential over time. Investors with a long horizon should monitor pipeline progress and debt reduction as key signals.
What is the main competitive advantage of Takeda?
Takeda's competitive positioning rests on its established presence in specialty therapeutic areas — particularly gastroenterology and rare diseases — where branded medicines face less generic competition and patient switching costs are high. However, UQS Score currently rates Takeda's Moat as Weak, indicating these advantages may not be as durable as peers.
What sector does TAK belong to?
Takeda operates in the Healthcare sector, specifically within the pharmaceutical industry. It focuses on prescription medicines rather than consumer health or medical devices, with a portfolio concentrated in specialty and rare disease categories that typically require significant R&D investment.
Unlock Full TAK Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown for TAK
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare TAK side-by-side with sector peers
- ✓Screen for Attractive-valuation large-cap healthcare stocks
- ✓Track quality score changes across quarterly earnings cycles
Pro Analysis
TAK — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 42.2 | 36.2 | 31.0 | 36.1 | 26.6 | 94.9 | -0.1 |
| May 17, 2026 | 42.3 | 36.2 | 31.0 | 36.1 | 26.6 | 95.4 | +8.8 |
| May 7, 2026 | 33.5 | 32.2 | 31.0 | 0.1 | 25.6 | 92.2 | -0.1 |
| Apr 26, 2026 | 33.6 | 32.2 | 31.0 | 0.1 | 25.6 | 93.0 | +0.4 |
| Apr 19, 2026 | 33.2 | 32.2 | 31.0 | 0.1 | 25.6 | 90.0 | 0.0 |
| Apr 18, 2026 | 33.2 | 32.2 | 31.0 | 0.1 | 25.6 | 90.4 | -1.5 |
| Apr 14, 2026 | 34.7 | 32.2 | 31.0 | 0.1 | 25.6 | 100.0 | -11.8 |
| Apr 13, 2026 | 46.5 | 35.5 | 50.0 | 31.1 | 25.6 | 100.0 | +11.8 |
| Apr 2, 2026 | 34.7 | 32.2 | 31.0 | 0.1 | 25.6 | 100.0 | — |
TAK — Pillar Breakdown
Quality
— 36.2/100 (25%)Takeda Pharmaceutical Company Limited has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 36.1/100 (20%)Takeda Pharmaceutical Company Limited shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 26.6/100 (15%)Takeda Pharmaceutical Company Limited presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 95.0/100 (15%)Takeda Pharmaceutical Company Limited appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 31/100 (25%)Takeda Pharmaceutical Company Limited operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TAK.
Score Composition
Financial Data
More Stock Analysis
How is the TAK UQS Score Calculated?
The UQS (Unified Quality Score) for Takeda Pharmaceutical Company Limited is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Takeda Pharmaceutical Company Limited's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Takeda Pharmaceutical Company Limited is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.